TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 11.8M
Gross Profit 5.5M 47.05%
Operating Income -8.5M -72.40%
Net Income 43.6M 370.24%
EPS (Diluted) $1.23

Balance Sheet Metrics

Total Assets 196.0M
Total Liabilities 36.6M
Shareholders Equity 159.4M
Debt to Equity 0.23

Cash Flow Metrics

Operating Cash Flow 47.8M
Free Cash Flow -15.2M

Revenue & Profitability Trend

908 Devices Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i59.6M50.2M46.9M42.2M26.9M
Cost of Goods Sold i29.8M24.9M20.8M19.0M12.0M
Gross Profit i29.9M25.3M26.0M23.2M14.9M
Gross Margin % i50.1%50.4%55.5%55.0%55.5%
Operating Expenses
Research & Development i25.5M21.9M17.5M13.1M8.2M
Selling, General & Administrative i53.6M46.2M43.9M32.2M12.5M
Other Operating Expenses i-----
Total Operating Expenses i79.1M68.1M61.4M45.3M20.7M
Operating Income i-49.3M-42.8M-35.4M-22.1M-5.8M
Operating Margin % i-82.6%-85.1%-75.5%-52.3%-21.6%
Non-Operating Items
Interest Income i4.5M6.5M2.0M548.0K-
Interest Expense i0201.0K129.0K486.0K976.0K
Other Non-Operating Income-27.7M-131.0K-83.0K-162.0K-6.0M
Pre-tax Income i-72.5M-36.6M-33.6M-22.2M-12.8M
Income Tax i-282.0K-211.0K0--
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-72.2M-36.4M-33.6M-22.2M-12.8M
Net Margin % i-121.1%-72.5%-71.6%-52.5%-47.7%
Key Metrics
EBITDA i-40.4M-34.0M-31.8M-20.8M-11.0M
EPS (Basic) i$-2.12$-1.13$-1.07$-0.79$-2.35
EPS (Diluted) i$-2.12$-1.13$-1.07$-0.79$-2.35
Basic Shares Outstanding i340763213223939431492531279579045485032
Diluted Shares Outstanding i340763213223939431492531279579045485032

Income Statement Trend

908 Devices Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i44.0M121.0M188.4M224.1M159.2M
Short-term Investments i25.6M24.6M0--
Accounts Receivable i12.6M9.0M10.0M16.4M6.8M
Inventory i16.2M14.9M12.5M7.9M4.6M
Other Current Assets4.7M4.2M4.7M4.5M-
Total Current Assets i103.1M173.8M215.6M252.9M171.0M
Non-Current Assets
Property, Plant & Equipment i17.2M14.5M10.6M10.0M10.7M
Goodwill i45.3M28.6M28.6M0-
Intangible Assets i45.3M7.9M8.5M--
Long-term Investments-----
Other Non-Current Assets829.0K1.4M1.4M1.2M723.0K
Total Non-Current Assets i56.4M29.2M27.0M8.0M7.9M
Total Assets i159.5M203.0M242.6M260.9M178.8M
Liabilities
Current Liabilities
Accounts Payable i2.1M1.2M1.4M1.4M1.0M
Short-term Debt i1.9M2.0M1.5M1.3M1.7M
Current Portion of Long-term Debt-----
Other Current Liabilities--1.2M--
Total Current Liabilities i25.1M22.5M19.2M14.8M10.8M
Non-Current Liabilities
Long-term Debt i4.7M3.9M18.0M19.5M20.2M
Deferred Tax Liabilities i2.0M2.4M2.7M0-
Other Non-Current Liabilities2.3M-555.0K-194.0K
Total Non-Current Liabilities i19.7M14.9M32.8M31.5M29.0M
Total Liabilities i44.9M37.5M52.0M46.3M39.8M
Equity
Common Stock i35.0K33.0K32.0K31.0K27.0K
Retained Earnings i-242.8M-170.6M-134.2M-100.6M-78.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i114.6M165.5M190.6M214.6M139.0M
Key Metrics
Total Debt i6.6M5.9M19.5M20.9M21.9M
Working Capital i77.9M151.2M196.4M238.1M160.1M

Balance Sheet Composition

908 Devices Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-72.2M-36.4M-33.6M-22.2M-12.8M
Depreciation & Amortization i4.7M2.4M1.6M925.0K831.0K
Stock-Based Compensation i11.8M9.8M7.2M2.5M525.0K
Working Capital Changes i-4.4M-3.1M2.1M-11.1M8.0M
Operating Cash Flow i-73.7M-27.3M-22.6M-29.6M-4.2M
Investing Activities
Capital Expenditures i-602.0K-2.0M-2.0M-737.0K-9.0K
Acquisitions i-44.8M0-13.8M0-
Investment Purchases i-55.5M-48.9M0--
Investment Sales i54.6M24.5M0--
Investing Cash Flow i-46.3M-26.4M-15.8M-737.0K-9.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-060.0M30.0M2.2M
Debt Repayment i0-15.0M-60.0M-30.0M-2.2M
Financing Cash Flow i-376.0K-15.9M1.2M109.7M137.1M
Free Cash Flow i-30.8M-27.1M-23.0M-29.8M4.1M
Net Change in Cash i-120.4M-69.7M-37.2M79.4M133.0M

Cash Flow Trend

908 Devices Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -2.95
Forward P/E -5.89
Price to Book 1.53
Price to Sales 3.47
PEG Ratio -5.89

Profitability Ratios

Profit Margin -28.13%
Operating Margin -64.20%
Return on Equity -53.40%
Return on Assets -15.39%

Financial Health

Current Ratio 4.98
Debt to Equity 2.98
Beta 0.37

Per Share Data

EPS (TTM) $-2.36
Book Value per Share $4.13
Revenue per Share $1.86

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mass227.3M-2.951.53-53.40%-28.13%2.98
Abbott Laboratories 228.6B16.484.5230.93%32.43%26.50
Boston Scientific 157.6B63.337.0311.55%13.55%53.09
Outset Medical 243.8M-0.371.61-87.65%-82.06%63.59
Cerus 250.2M-11.954.52-35.56%-9.81%176.07
Quantum-Si 230.8M-1.610.95-46.87%52.32%5.04

Financial data is updated regularly. All figures are in the company's reporting currency.